Production (Stage)
D
Verastem, Inc. VSTM
$8.31 $0.8311.10% NASDAQ
Recommendation
Prev Close
$8.31
Volume
5,318,513
Avg Vol (90D)
1,158,619
Market Cap
$456.63M
Dividend & Yield
--
52-Week Range
$2.10 - $8.45
P/E (TTM)
--
EPS (TTM)
-$3.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Verastem (VSTM, $8.31) Aroon Indicator entered an Uptrend on May 23, 2025.
5/24/2025 - Tickeron - Stocks
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA)
5/23/2025 - TipRanks Financial Blog
Verastem (VSTM, $7.48) Aroon Indicator entered an Uptrend on May 22, 2025.
5/23/2025 - Tickeron - Stocks
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus ...
5/22/2025 - GuruFocus
Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial VSTM Stock News
5/22/2025 - GuruFocus
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC
5/22/2025 - TipRanks Financial Blog
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC
5/22/2025 - The Fly
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
5/22/2025 - Business Wire
Sherbrooke Park Advisers LLC Buys New Holdings in Verastem, Inc. (NASDAQ:VSTM)
5/22/2025 - Ticker Report
Verastem (VSTM, $7.61) Aroon Indicator entered an Uptrend on May 21, 2025.
5/22/2025 - Tickeron - Stocks
Verastem (VSTM, $8.03) Aroon Indicator entered an Uptrend on May 20, 2025.
5/21/2025 - Tickeron - Stocks
Soleus Capital Management L.P. Reduces Stock Position in Verastem, Inc. (NASDAQ:VSTM)
5/21/2025 - MarketBeat
Insider Selling: Verastem, Inc. (NASDAQ:VSTM) CFO Sells 11,143 Shares of Stock
5/21/2025 - MarketBeat
Tempus AI (TEM) Joins Forces with Verastem Oncology for Diagnostic Test Development
5/20/2025 - GuruFocus
Tempus AI Inc Collaborates with Verastem Oncology to Develop Companion Diagnostic Test TEM ...
5/20/2025 - GuruFocus
Tempus AI teams up with Verastem for companion diagnostic test
5/20/2025 - SeekingAlpha.com: All News
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved ...
5/20/2025 - GuruFocus
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved ...
5/20/2025 - GuruFocus
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
5/20/2025 - Business Wire
Verastem (VSTM, $7.59) RSI Indicator left the overbought zone on May 16, 2025
5/17/2025 - Tickeron - Technical Analysis
Verastem (VSTM, $7.93) RSI Indicator left the overbought zone on May 15, 2025
5/16/2025 - Tickeron - Stocks
Verastem (VSTM, $7.93) price may drop as it broke higher Bollinger Band on May 15, 2025
5/16/2025 - Tickeron - Stocks
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 177,855 Shares of Verastem, Inc. (NASDAQ:VSTM)
5/15/2025 - MarketBeat
Verastem (VSTM, $7.46) entered Downtrend as Momentum indicator drops below 0 level on May 14, 2025
5/15/2025 - Tickeron - Technical Analysis
Alliance Global Partners Sticks to Its Buy Rating for Verastem (VSTM)
5/14/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$10.00M
EBITDA (TTM)
-$131.04M
EBIT (TTM)
-$131.07M
Net Income (TTM)
-$148.88M
Balance Sheet
Total Assets (Q)
$131.70M
Total Debt (Q)
$76.80M
Total Liabilities (Q)
$164.13M
Book Value Per Share (Q)
-$0.6299
Cash Flow
Cash from Operations (TTM)
-$115.14M
Cash from Investing (TTM)
$28.99M
Cash from Financing (TTM)
$121.36M
Net Change in Cash (TTM)
$35.22M
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
2.11
7-Day Total Return
4.79%
30-Day Total Return
79.09%
60-Day Total Return
48.53%
90-Day Total Return
56.50%
Year to Date Total Return
28.04%
1-Year Total Return
101.70%
2-Year Total Return
56.32%
3-Year Total Return
-44.60%
5-Year Total Return
-61.53%
52-week Low
Aug 05, 2024 - $2.10
52-week High
May 20, 2025 - $8.45
Valuation
Market Cap
$456.63M - Small Cap
Enterprise Value
$415.85M
Price/Sales (TTM)
45.04
Price/Book (Q)
-13.19
Dividends and Shares
Shares Outstanding
54.17M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.verastem.com
Phone Number
781 292 4200
Address
117 Kendrick Street
Needham, MA 02494
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed